Documents Shed Light on Cam Garners Stealth Venture
Summary
Questcor said it realized net proceeds of $448,000 from the sale, suggesting Garner’s company picked up the nasal spray for a song.Diabetics are prone to this condition because high blood sugar levels can damage the nerve that controls the stomach and intestinal muscles.Questcor, in some earlier SEC filings, argued that a nasal spray offered an easier route of administration to people with digestive problems.Specifically, the FDA said using metoclopromide for more than three months carried a risk of tardive dyskinesia—involuntary and repetitive movements—such as grimacing or lip-smacking, that remain when the drug is discontinued.Reading between the lines, it looked like Evoke had hoped to use nine-year-old data from Questcor’s mid-stage trial to obtain FDA sign-off on a late-stage study.